Business Description
Alimera Sciences Inc
NAICS : 325412
SIC : 2834
ISIN : US0162591038
Description
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East operations are managed as three operating segments: U.S., International and Operating Cost It generates maximum revenue from U.S. Segment.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.19 | |||||
| Equity-to-Asset | 0.3 | |||||
| Debt-to-Equity | 1.42 | |||||
| Debt-to-EBITDA | -58.58 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -2.18 | |||||
| Beneish M-Score | -0.87 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -31.7 | |||||
| 3-Year EPS without NRI Growth Rate | 19.3 | |||||
| 3-Year FCF Growth Rate | -85.5 | |||||
| Future 3-5Y Total Revenue Growth Rate | 18.87 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.54 | |||||
| 9-Day RSI | 55.65 | |||||
| 14-Day RSI | 52.41 | |||||
| 6-1 Month Momentum % | 15.91 | |||||
| 12-1 Month Momentum % | 120.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.39 | |||||
| Quick Ratio | 2.31 | |||||
| Cash Ratio | 0.55 | |||||
| Days Inventory | 50.62 | |||||
| Days Sales Outstanding | 116.72 | |||||
| Days Payable | 284.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -109.2 | |||||
| Shareholder Yield % | -9.02 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 86.58 | |||||
| Operating Margin % | -2.39 | |||||
| Net Margin % | -24.93 | |||||
| FCF Margin % | -110.97 | |||||
| ROE % | -99.16 | |||||
| ROA % | -18.19 | |||||
| ROIC % | -2.22 | |||||
| ROC (Joel Greenblatt) % | -52.91 | |||||
| ROCE % | -11.06 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 123.62 | |||||
| PS Ratio | 0.7 | |||||
| PB Ratio | 4.21 | |||||
| EV-to-EBIT | -25.1 | |||||
| EV-to-Forward-EBIT | 32.47 | |||||
| EV-to-EBITDA | -221.97 | |||||
| EV-to-Revenue | 3.06 | |||||
| EV-to-Forward-Revenue | 2.39 | |||||
| EV-to-FCF | -2.76 | |||||
| Price-to-Median-PS-Value | 0.47 | |||||
| Earnings Yield (Greenblatt) % | -3.98 | |||||
| FCF Yield % | -46.23 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers